scispace - formally typeset
F

Fernando Rico-Villademoros

Researcher at Spanish National Research Council

Publications -  86
Citations -  3322

Fernando Rico-Villademoros is an academic researcher from Spanish National Research Council. The author has contributed to research in topics: Fibromyalgia & Tolerability. The author has an hindex of 29, co-authored 83 publications receiving 3045 citations. Previous affiliations of Fernando Rico-Villademoros include University of Granada & University of Alcalá.

Papers
More filters
Journal Article

Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction.

TL;DR: In this article, the authors analyzed the incidence of antidepressant-related sexual dysfunction in a multicenter, prospective, open-label study carried out by the Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction.
Journal Article

Incidence of Sexual Dysfunction Associated With Antidepressant Agents: A Prospective Multicenter Study of 1022 Outpatients

TL;DR: The incidence of sexual dysfunction with SSRIs and venlafaxine is high, ranging from 58% to 73%, as compared with serotonin-2 (5-HT2) blockers (nefazodone and mirtazapine), moclobemide, and amineptine.
Journal ArticleDOI

Frequency of Sexual Dysfunction and Other Reproductive Side-effects in Patients with Schizophrenia Treated with Risperidone, Olanzapine, Quetiapine, or Haloperidol: The Results of the EIRE Study

TL;DR: The results suggest that none of the atypical antipsychotics that were studied significantly improved sexual dysfunction and other reproductive side-effects of the conventional antipsychotic, haloperidol, in stabilized patients during long-term treatment.
Journal ArticleDOI

Alpha2delta ligands, gabapentin, pregabalin and mirogabalin: a review of their clinical pharmacology and therapeutic use

TL;DR: Gabapentin and pregabalin are effective for the treatment neuropathic pain, fibromyalgia and epilepsy; in addition, they may be useful for the reduction of postoperative pain.
Journal ArticleDOI

Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study.

TL;DR: Clinically relevant weight gain is clearly associated with olanzapine, and to lesser extent, with haloperidol and risperidone.